绥美凯应该怎么使用？

For the treatment of adults and adolescents over 12 years old (weighing at least 40kg) infected with human immunodeficiency virus (HIV).

HIV-infected patients, regardless of race, should be screened for the HLA-B*5701 allele before starting treatment with abacavir-containing products. If a patient is known to carry the RLA-B*5701 allele and should not take products containing abacavir, how should SuimeiKai be used?

How to use Suimeikai: Suimeike should be taken under the guidance of a physician with experience in HIV infection.

For adults and adolescents, the recommended dose of Trimax is one tablet once daily.

Adults or adolescents whose body weight is less than 40 kg should not be given Trimax because Trimax is a fixed-dose tablet and the dose cannot be reduced.

Trimax is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these circumstances, physicians should refer to the respective product information for these medicines.

Miss a dose

If the patient misses a dose of Suimei Kai and there are more than 4 hours before the next dose, Sui Meikai should be taken as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule.

elderly patients

There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients aged ≥65 years, and there is no evidence that older patients require different doses than younger adults. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when using in this age group.

Recommended related hot articles: /newsDetail/71908.html